Citigroup
KZR

Citigroup’s Kezar Life Sciences KZR Stock Holding History

Citigroup’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51
Closed -$199 – 6278
2025
Q3 		$199 Hold
51
– – ﹤0.01% 5765
2025
Q2 		$234 Hold
51
– – ﹤0.01% 5472
2025
Q1 		$249 Hold
51
– – ﹤0.01% 5409
2024
Q4 		$343 Sell
51
-1
-2% -$7 ﹤0.01% 5640
2024
Q3 		$401 Sell
52
-969
-95% -$5.84K ﹤0.01% 5491
2024
Q2 		$6.13K Sell
1,021
-539
-35% -$4.1K ﹤0.01% 5228
2024
Q1 		$14.1K Buy
1,560
+483
+45% +$4.4K ﹤0.01% 5124
2023
Q4 		$10.2K Buy
1,077
+980
+1,010% +$8.61K ﹤0.01% 5191
2023
Q3 		$1.16K Sell
97
-2,152
-96% -$38.1K ﹤0.01% 5075
2023
Q2 		$55.1K Sell
2,249
-17,770
-89% -$463K ﹤0.01% 4590
2023
Q1 		$627K Buy
20,019
+4,684
+31% +$271K ﹤0.01% 2950
2022
Q4 		$1.08M Sell
15,335
-6,999
-31% -$519K ﹤0.01% 2546
2022
Q3 		$1.92M Buy
22,334
+21,805
+4,122% +$2.12M ﹤0.01% 2169
2022
Q2 		$44K Sell
529
-1,792
-77% -$158K ﹤0.01% 4592
2022
Q1 		$386K Sell
2,321
-4,047
-64% -$581K ﹤0.01% 3677
2021
Q4 		$1.06M Buy
6,368
+5,736
+908% +$648K ﹤0.01% 3185
2021
Q3 		$55K Buy
632
+165
+35% +$10.9K ﹤0.01% 4687
2021
Q2 		$25K Sell
467
-31
-6% -$1.76K ﹤0.01% 5173
2021
Q1 		$30K Sell
498
-405
-45% -$23.7K ﹤0.01% 5005
2020
Q4 		$47K Buy
903
+548
+154% +$30.5K ﹤0.01% 6079
2020
Q3 		$17K Sell
355
-42
-11% -$2.01K ﹤0.01% 6297
2020
Q2 		$20K Sell
397
-509
-56% -$25.7K ﹤0.01% 6609
2020
Q1 		$39K Buy
906
+592
+189% +$24.1K ﹤0.01% 6199
2019
Q4 		$13K Buy
314
+217
+224% +$6.68K ﹤0.01% 7108
2019
Q3 		$3K Sell
97
-305
-76% -$14.7K ﹤0.01% 7462
2019
Q2 		$31K Buy
402
+56
+16% +$8.71K ﹤0.01% 6838
2019
Q1 		$61K Buy
346
+210
+154% +$41.4K ﹤0.01% 6174
2018
Q4 		$32K Sell
136
-8
-6% -$1.96K ﹤0.01% 6574
2018
Q3 		$31K Buy
+144
New +$25.1K ﹤0.01% 6869

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citigroup's KZR Position: Q4 2025 in Review

Citigroup sold out of Kezar Life Sciences (KZR) in Q4 2025, closing a stake of 51 shares — an estimated $199 sold.

Citigroup first reported a position in KZR in Q3 2018 and held it in 29 quarters. The position peaked at $1.92M in Q3 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2025.

  • Citigroup reported no remaining Kezar Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 51 Kezar Life Sciences shares in Q4 2025, an estimated $199.
  • Citigroup first reported a position in Kezar Life Sciences in Q3 2018 and held it in 29 quarters.
  • Citigroup's Kezar Life Sciences position peaked at $1.92M in Q3 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.